Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John G. Cox
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 289
- Beta
- 1.08
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 2.83
Financials
Revenue
$0.00-100.0%Net Income
$-178.56MEBITDA
$-173.40M-155.2%Free Cash Flow
$-131.80M-151.9%EPS (diluted)
$-1.08Shares Outstanding (diluted)
165.45M+18.2%Operating Expenses
$181.66MCash & Debt
$898.48MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-446.21M | $-3.47 |
| 2024 | $0.00 | $-317.42M | $-3.37 |
| 2023 | $0.00 | $-235.94M | $-3.95 |
| 2022 | $0.00 | $-168.10M | $-3.23 |
| 2021 | $0.00 | $-149.29M | $-2.93 |
| 2020 | $0.00 | $-58.74M | $-1.24 |
| 2019 | $0.00 | $-13.54M | $-0.30 |
| 2018 | $0.00 | $-4.81M | $-0.47 |
| 2017 | $506.00M | $76.00M | $0.47 |
| 2016 | $1.37B | $-1.24B | $-9.61 |
| 2015 | $842.00M | $50.00M | $0.40 |
| 2014 | $1.47B | $-67.00M | $-0.53 |
| 2013 | $3.00M | $-356.00M | $-3.56 |
| 2012 | $3.00M | $87.00M | $0.87 |
Valuation
DYNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·6d ago·Neutral
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months -
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort -
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
…hich are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present preclinical data…
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Dyne Therapeutics to Participate in Upcoming Investor Conferences WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:
View source ↗ - News (RSS)investing·54d ago·Neutral
Dyne Therapeutics stock hits 52-week high at 27.19 USD
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.91 per share
Typical surprise +2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-1.08 vs $-0.75miss
- Mon, May 11$-0.73 vs $-0.77beat
- Mon, Mar 2$-0.76 vs $-0.74miss
- Wed, Nov 5$-0.76 vs $-0.81beat
- Mon, Jul 28$-0.97 vs $-0.99beat
- Thu, May 8$-1.05 vs $-0.88miss
Estimates and results for DYN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DYN officers and directors.
- Bought
- $157k
- Sold
- $127.1m
4 trades
86 trades
- Friedl-naderer Johannasold
- Kerr Douglassold
- Cox Johnsold
- Friedl-naderer Johannasold
- Kerr Douglassold
- Rhodes Jason Psold
- Rhodes Jason Psold
- Rhodes Jason Psold
10 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DYN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.